What We Know About Donald Trump’s COVID-19 Treatment Plan

The President was hospitalized on Friday evening and has been receiving an aggressive treatment of experimental and standard drugs.

Written byLisa Winter
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

ABOVE: © ISTOCK.COM, WELLESENTERPRISES

On Thursday, October 1, it was announced that President Donald Trump, First Lady Melania Trump, and other White House officials had tested positive for SARS-CoV-2. His symptoms worsened and on Friday evening, he was admitted to Walter Reed National Military Medical Center in Bethesda, Maryland.

There has been some mixed messaging with the actual timeline of when he received his diagnosis and began a treatment regimen, as The New York Times reports, and doctors can only speculate on his prognosis.

Here is what is currently known about the drugs Trump has been taking to combat his illness:

One of the first reported treatments Trump received was an experimental cocktail of two monoclonal antibodies from Regeneron. Trump was intravenously given eight grams of the cocktail, which is the highest dose used during the drug’s small, 245-person clinical trial. According to a September press release from Regeneron, the ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • Lisa joined The Scientist in 2017. As social media editor, some of her duties include creating content, managing interactions, and developing strategies for the brand’s social media presence. She also contributes to the News & Opinion section of the website. Lisa holds a degree in Biological Sciences with a concentration in genetics, cell, and developmental biology from Arizona State University and has worked in science communication since 2012.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies